Synopsis
Synopsis
0
EU WC
0
VMF
0
Europe
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Finished Drug Prices
NA
1. 88755-39-9
2. Chembl2000337
3. Runx1/eto Tetramerization-in-1
4. Nsc162496
5. Schembl16211954
6. Dtxsid40864143
7. Bdbm50392853
8. 2,3]dioxol-5-yl)-4-oxobutanoic Acid
9. Nsc-162496
10. Hy-151411
11. Cs-0611487
12. Ft-0627100
13. A937131
14. Butanoic Acid,4-bis[1,3-benzodioxol-5-yl]-4-oxo-
15. 2,4-bis(2h-1,3-benzodioxol-5-yl)-4-oxobutanoic Acid
Molecular Weight | 342.3 g/mol |
---|---|
Molecular Formula | C18H14O7 |
XLogP3 | 2.4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 5 |
Exact Mass | 342.07395278 g/mol |
Monoisotopic Mass | 342.07395278 g/mol |
Topological Polar Surface Area | 91.3 Ų |
Heavy Atom Count | 25 |
Formal Charge | 0 |
Complexity | 522 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3405
Submission : 1979-01-09
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16273
Submission : 2002-11-25
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4489
Submission : 1982-02-02
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16622
Submission : 2003-05-30
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26086
Submission : 2012-05-24
Status : Inactive
Type : II
Certificate Number : R0-CEP 2001-364 - Rev 01
Issue Date : 2005-03-18
Type : TSE
Substance Number : 912
Status : Expired
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 90
Submission : 1954-03-04
Status : Inactive
Type : II
Certificate Number : R1-CEP 2001-085 - Rev 02
Issue Date : 2010-06-01
Type : TSE
Substance Number : 912
Status : Valid
Registration Number : 304MF10126
Registrant's Address : 14191 Myford Road Tustin, CA 92780, USA
Initial Date of Registration : 2022-08-24
Latest Date of Registration : --
Registration Number : 302MF10030
Registrant's Address : 1300 South Patterson Drive, Bloomington, Indiana 47403 USA
Initial Date of Registration : 2020-02-20
Latest Date of Registration : --
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4489
Submission : 1982-02-02
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16273
Submission : 2002-11-25
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26086
Submission : 2012-05-24
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16622
Submission : 2003-05-30
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3405
Submission : 1979-01-09
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 90
Submission : 1954-03-04
Status : Inactive
Type : II
Hyaluronidase, Product Codes: 081231, 081236, 08...
Certificate Number : R1-CEP 2001-085 - Rev 02
Status : Valid
Issue Date : 2010-06-01
Type : TSE
Substance Number : 912
Certificate Number : R1-CEP 2001-068 - Rev 00
Status : Suspended by EDQM GMP non-compliance
Issue Date : 2007-04-04
Type : TSE
Substance Number : 912
Hyaluronidase, Type VIII, (Product Number H2032)
Certificate Number : R0-CEP 2001-364 - Rev 01
Status : Expired
Issue Date : 2005-03-18
Type : TSE
Substance Number : 912
Borhyaluronidase alpha (genetical recombination)
Registration Number : 304MF10126
Registrant's Address : 14191 Myford Road Tustin, CA 92780, USA
Initial Date of Registration : 2022-08-24
Latest Date of Registration : 2022-08-24
Borhyaluronidase alpha (genetical recombination)
Registration Number : 302MF10030
Registrant's Address : 1300 South Patterson Drive, Bloomington, Indiana 47403 USA
Initial Date of Registration : 2020-02-20
Latest Date of Registration : 2021-09-02
Registrant Name : Korea BMI Co., Ltd.
Registration Date : 2023-12-27
Registration Number : 20231227-210-J-1591
Manufacturer Name : Korea BMI Co., Ltd.
Manufacturer Address : 11, Cheomdan-ro 7-gil, Jeju-si, Jeju Special Self-Governing Province, Factory 2
Registrant Name : Humedics Co., Ltd.
Registration Date : 2024-03-13
Registration Number : 20240313-210-J-1620
Manufacturer Name : Humedics Co., Ltd.
Manufacturer Address : 17 Biovalley 2-ro, Jecheon-si, Chungcheongbuk-do
Registrant Name : Humedics Co., Ltd.
Registration Date : 2024-03-13
Registration Number : 20240313-210-J-1619
Manufacturer Name : Humedics Co., Ltd.
Manufacturer Address : 17 Biovalley 2-ro, Jecheon-si, Chungcheongbuk-do
Registrant Name : Korea Chorus Co., Ltd.
Registration Date : 2023-07-04
Registration Number : 20230704-210-J-1516
Manufacturer Name : Ningbo Linzyme Biosciences C...
Manufacturer Address : 8, Xingshun Road, Binhai New City, Xiaocao'e Town, Yuyao@11, Geodudanji 1-gil, Dongna...
Registrant Name : Insung Trading Co., Ltd.
Registration Date : 2021-12-07
Registration Number : 20211207-210-J-1171
Manufacturer Name : Ningbo Linzyme Biosciences C...
Manufacturer Address : 8, Xingshun Road, Binhai New city, Xiaocaoe town, Yuyao
Registrant Name : Korea BMI Co., Ltd.
Registration Date : 2024-09-02
Registration Number : 20240902-210-J-1684
Manufacturer Name : Korea BMI Co., Ltd.
Manufacturer Address : 11, Cheomdan-ro 7-gil, Jeju-si, Jeju Special Self-Governing Province
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 52221-201
Start Marketing Date : 2015-06-17
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
About the Company : Bioindustria Laboratorio Italiano Medicinali L.I.M. S.p.A. has a long tradition in the pharmaceutical business and specializes in: large and small volume injectables with termin...
About the Company : The company is a professional manufacturer of active biological extracts. We adhere to the market-oriented business philosophy. The international and domestic markets take advantag...
Details:
Vyvgart Hytrulo, a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment, and recombinant human hyaluronidase PH20, It is being developed for CIDP.
Lead Product(s): Efgartigimod Alfa,Hyaluronidase
Therapeutic Area: Neurology Brand Name: Vyvgart Hytrulo
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2024
Lead Product(s) : Efgartigimod Alfa,Hyaluronidase
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Argenx Progresses Efgartigimod SC in Idiopathic Inflammatory Myopathies Studies
Details : Vyvgart Hytrulo, a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment, and recombinant human hyaluronidase PH20, It is being developed for CIDP.
Brand Name : Vyvgart Hytrulo
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 20, 2024
Details:
Vyvgart Hytrulo, a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment and recombinant human hyaluronidase PH20, it is indicated for CIPD.
Lead Product(s): Efgartigimod Alfa,Hyaluronidase
Therapeutic Area: Neurology Brand Name: Vyvgart Hytrulo
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Zai Lab
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2024
Lead Product(s) : Efgartigimod Alfa,Hyaluronidase
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Zai Lab
Deal Size : Not Applicable
Deal Type : Not Applicable
Argenx and Zai Lab Announce Approval of VYVGART for CIDP in China
Details : Vyvgart Hytrulo, a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment and recombinant human hyaluronidase PH20, it is indicated for CIPD.
Brand Name : Vyvgart Hytrulo
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 11, 2024
Details:
Darzalex Faspro (daratumumab and hyaluronidase-fihj) in is being investgated as monotherapy for the treatment of adult patients with high-risk smouldering multiple myeloma.
Lead Product(s): Daratumumab,Hyaluronidase
Therapeutic Area: Oncology Brand Name: Darzalex Faspro
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2024
Lead Product(s) : Daratumumab,Hyaluronidase
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Johnson & Johnson Submits DARZALEX® Applications for Myeloma Approval
Details : Darzalex Faspro (daratumumab and hyaluronidase-fihj) in is being investgated as monotherapy for the treatment of adult patients with high-risk smouldering multiple myeloma.
Brand Name : Darzalex Faspro
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 08, 2024
Details:
Argenx gains access to Halozyme's ENHANZE, a proprietary rHuPH20 enzyme for subcutaneous drug delivery, for six targets, including FcRn target, Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase).
Lead Product(s): Efgartigimod Alfa,Hyaluronidase
Therapeutic Area: Immunology Brand Name: Vyvgart Hytrulo
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Argenx
Deal Size: $370.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration October 03, 2024
Lead Product(s) : Efgartigimod Alfa,Hyaluronidase
Therapeutic Area : Immunology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Argenx
Deal Size : $370.0 million
Deal Type : Collaboration
Halozyme Expands Global Collaboration and License Agreement with Argenx for ENHANZE®
Details : Argenx gains access to Halozyme's ENHANZE, a proprietary rHuPH20 enzyme for subcutaneous drug delivery, for six targets, including FcRn target, Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase).
Brand Name : Vyvgart Hytrulo
Molecule Type : Large molecule
Upfront Cash : $30.0 million
October 03, 2024
Details:
Talvey (talquetamab, CD3 targeting) with Darzalex Faspro (daratumumab and hyaluronidase, CD38 targeting) antibodies are being investigated in patients with relapsed or refractory multiple myeloma.
Lead Product(s): Talquetamab,Daratumumab,Hyaluronidase
Therapeutic Area: Oncology Brand Name: Talvey
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2024
Lead Product(s) : Talquetamab,Daratumumab,Hyaluronidase
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
TALVEY® And DARZALEX® Combo Shows Durable Responses in Multiple Myeloma
Details : Talvey (talquetamab, CD3 targeting) with Darzalex Faspro (daratumumab and hyaluronidase, CD38 targeting) antibodies are being investigated in patients with relapsed or refractory multiple myeloma.
Brand Name : Talvey
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 27, 2024
Details:
Ocrevus Zunovo (ocrelizumab-hyaluronidase) is a humanised mAb-enzyme designed to target CD20-positive B cells, approved for the treatment of multiple sclerosis.
Lead Product(s): Ocrelizumab,Hyaluronidase
Therapeutic Area: Neurology Brand Name: Ocrevus Zunovo
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2024
Lead Product(s) : Ocrelizumab,Hyaluronidase
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves Ocrevus Zunovo as First Twice-a-Year Subcutaneous Injection for MS
Details : Ocrevus Zunovo (ocrelizumab-hyaluronidase) is a humanised mAb-enzyme designed to target CD20-positive B cells, approved for the treatment of multiple sclerosis.
Brand Name : Ocrevus Zunovo
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 13, 2024
Details:
Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone is approved in the U.S. for patients with newly diagnosed multiple myeloma.
Lead Product(s): Daratumumab,Hyaluronidase,Bortezomib
Therapeutic Area: Oncology Brand Name: Darzalex Faspro
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2024
Lead Product(s) : Daratumumab,Hyaluronidase,Bortezomib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
DARZALEX FASPRO® Quadruplet Regimen Approved for Newly Diagnosed Multiple Myeloma
Details : Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone is approved in the U.S. for patients with newly diagnosed multiple myeloma.
Brand Name : Darzalex Faspro
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 30, 2024
Details:
Vyvgart Hytrulo, a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment, and recombinant human hyaluronidase PH20, It is being developed for CIDP.
Lead Product(s): Efgartigimod Alfa,Hyaluronidase
Therapeutic Area: Neurology Brand Name: Vyvgart Hytrulo
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2024
Lead Product(s) : Efgartigimod Alfa,Hyaluronidase
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approval of VYVGART Hytrulo for Inflammatory Demyelinating Polyneuropathy
Details : Vyvgart Hytrulo, a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment, and recombinant human hyaluronidase PH20, It is being developed for CIDP.
Brand Name : Vyvgart Hytrulo
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 21, 2024
Details:
Darzalex Faspro (daratumumab and hyaluronidase-fihj) with bortezomib, lenalidomide, and dexamethasone is evaluated in phase 3 trials for maintenance in newly diagnosed myeloma.
Lead Product(s): Daratumumab,Hyaluronidase,Lenalidomide
Therapeutic Area: Oncology Brand Name: Darzalex Faspro
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Lead Product(s) : Daratumumab,Hyaluronidase,Lenalidomide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Johnson & Johnson Submits Biologics License Application for DARZALEX FASPRO®
Details : Darzalex Faspro (daratumumab and hyaluronidase-fihj) with bortezomib, lenalidomide, and dexamethasone is evaluated in phase 3 trials for maintenance in newly diagnosed myeloma.
Brand Name : Darzalex Faspro
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 30, 2024
Details:
Hyqvia is a liquid medicine containing Recombinant Human Hyaluronidase and immunoglobulins. It is approved as maintenance therapy in patients with chronic inflammatory demyelinating polyneuropathy.
Lead Product(s): Immune Globulin,Hyaluronidase
Therapeutic Area: Neurology Brand Name: HyQvia
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Lead Product(s) : Immune Globulin,Hyaluronidase
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Takeda’s HYQVIA® Approved in Europe for Chronic Inflammatory Demyelinating Polyneuropathy
Details : Hyqvia is a liquid medicine containing Recombinant Human Hyaluronidase and immunoglobulins. It is approved as maintenance therapy in patients with chronic inflammatory demyelinating polyneuropathy.
Brand Name : HyQvia
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 29, 2024
RLD :
TE Code :
Brand Name : HYDASE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 150 UNITS/ML
Approval Date :
Application Number : 21716
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : AMPHADASE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 150 UNITS/ML
Approval Date :
Application Number : 21665
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : VITRASE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 6,200 UNITS/VIAL
Approval Date :
Application Number : 21640
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : VITRASE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 200 UNITS/VIAL
Approval Date :
Application Number : 21640
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
HYALURONIDASE RECOMBINANT HUMAN
Brand Name : HYLENEX RECOMBINANT
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 150 UNITS/ML
Approval Date :
Application Number : 21859
RX/OTC/DISCN :
RLD :
TE Code :
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Hyalase
Dosage Form : INJ
Dosage Strength : 1500u.i.
Packaging : 1X10u.i.
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Related Excipient Companies
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral, Topical
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Application : Parenteral
Excipient Details : Histidine is used in biotherapeutic formulations and protects monoclonal antibodies in both the liquid and lyophilized state.
Pharmacopoeia Ref : USP, EP, BP, JP, ChP
Technical Specs : pH 7.4
Ingredient(s) : L-Histidine Excipient
Dosage Form : Injectable / Parenteral
Grade : Parenteral and Nasal
Application : Parenteral
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : CALCIUM CHLORIDE DIHYDRATE Excipient
Dosage Form : Tablet
Grade : Oral
Brand Name : Calcium Chloride Dihydrat...
Application : Fillers, Diluents & Binders
Excipient Details : A & C's Calcium Chloride Dihydrate multi-compendial is an excipient, which meets USP-NF, EP and BP monographs.
Pharmacopoeia Ref : Multi-compendial
Technical Specs : Not Available
Ingredient(s) : CALCIUM CHLORIDE DIHYDRATE Excipient
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Brand Name : Glycerol Multi-Compendial
Application : Parenteral
Excipient Details : A & C's Glycerol multi-compendial is an excipient that meets USP-NF, EP and BP monographs.
Pharmacopoeia Ref : Multi-compendial
Technical Specs : Not Available
Ingredient(s) : Glycerol Excipient
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Application : Parenteral
Excipient Details : A & C's Glycerol is an excipient which meets the USP monograph.
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Brand Name : NaCl Multi-compendial Low...
Application : Parenteral
Excipient Details : A & C's Sodium Chloride multi-compendial low endotoxin is an excipient meeting USP-NF, EP, BP and JP monographs.
Pharmacopoeia Ref : Multi-compendial
Technical Specs : Low Endotoxin
Ingredient(s) : Sodium Chloride Excipient
Dosage Form : Capsule
Grade : Oral
Brand Name : Polysorbate 80 Multi-Comp...
Application : Solubilizers
Excipient Details : A & C's Polysorbate 80 multi-compendial is an excipient which meets USP-NF, EP, BP and JP monographs.
Dosage Form : Capsule
Grade : Oral
Brand Name : Polysorbate 80 NF
Application : Solubilizers
Excipient Details : A & C's Polysorbate 80 is an excipient which meets the NF monograph.
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Brand Name : Sodium Chloride USP
Application : Parenteral
Excipient Details : A & C's Sodium Chloride is an excipient meeting the USP monograph.
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Application : Parenteral
Excipient Details : A&C’s Thimerosal USP 10% aqueous solution is a preservative that meets the USP monograph.
Pharmacopoeia Ref : USP
Technical Specs : 10% (w/v) Aqueous Solution
Ingredient(s) : Thimerosal Excipient
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Hyaluronidase manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Hyaluronidase, including repackagers and relabelers. The FDA regulates Hyaluronidase manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Hyaluronidase API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Hyaluronidase manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Hyaluronidase supplier is an individual or a company that provides Hyaluronidase active pharmaceutical ingredient (API) or Hyaluronidase finished formulations upon request. The Hyaluronidase suppliers may include Hyaluronidase API manufacturers, exporters, distributors and traders.
click here to find a list of Hyaluronidase suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Hyaluronidase DMF (Drug Master File) is a document detailing the whole manufacturing process of Hyaluronidase active pharmaceutical ingredient (API) in detail. Different forms of Hyaluronidase DMFs exist exist since differing nations have different regulations, such as Hyaluronidase USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Hyaluronidase DMF submitted to regulatory agencies in the US is known as a USDMF. Hyaluronidase USDMF includes data on Hyaluronidase's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Hyaluronidase USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Hyaluronidase suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Hyaluronidase Drug Master File in Japan (Hyaluronidase JDMF) empowers Hyaluronidase API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Hyaluronidase JDMF during the approval evaluation for pharmaceutical products. At the time of Hyaluronidase JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Hyaluronidase suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Hyaluronidase Drug Master File in Korea (Hyaluronidase KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Hyaluronidase. The MFDS reviews the Hyaluronidase KDMF as part of the drug registration process and uses the information provided in the Hyaluronidase KDMF to evaluate the safety and efficacy of the drug.
After submitting a Hyaluronidase KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Hyaluronidase API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Hyaluronidase suppliers with KDMF on PharmaCompass.
A Hyaluronidase CEP of the European Pharmacopoeia monograph is often referred to as a Hyaluronidase Certificate of Suitability (COS). The purpose of a Hyaluronidase CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Hyaluronidase EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Hyaluronidase to their clients by showing that a Hyaluronidase CEP has been issued for it. The manufacturer submits a Hyaluronidase CEP (COS) as part of the market authorization procedure, and it takes on the role of a Hyaluronidase CEP holder for the record. Additionally, the data presented in the Hyaluronidase CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Hyaluronidase DMF.
A Hyaluronidase CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Hyaluronidase CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Hyaluronidase suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Hyaluronidase as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Hyaluronidase API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Hyaluronidase as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Hyaluronidase and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Hyaluronidase NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Hyaluronidase suppliers with NDC on PharmaCompass.
Hyaluronidase Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Hyaluronidase GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Hyaluronidase GMP manufacturer or Hyaluronidase GMP API supplier for your needs.
A Hyaluronidase CoA (Certificate of Analysis) is a formal document that attests to Hyaluronidase's compliance with Hyaluronidase specifications and serves as a tool for batch-level quality control.
Hyaluronidase CoA mostly includes findings from lab analyses of a specific batch. For each Hyaluronidase CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Hyaluronidase may be tested according to a variety of international standards, such as European Pharmacopoeia (Hyaluronidase EP), Hyaluronidase JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Hyaluronidase USP).
LOOKING FOR A SUPPLIER?